S
MYGN icon

Surevest’s Myriad Genetics MYGN Stock Holding History

Surevest’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4K Hold
206
– – ﹤0.01% 340
2022
Q2 		$4K Hold
206
– – ﹤0.01% 355
2022
Q1 		$5K Hold
206
– – ﹤0.01% 321
2021
Q4 		$6K Buy
+206
New +$5.97K ﹤0.01% 311

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Surevest's MYGN Position: Q3 2022 in Review

Surevest held its Myriad Genetics (MYGN) position steady in Q3 2022 at 206 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

Surevest first reported a position in MYGN in Q4 2021 and has held it in 4 quarters since. The position peaked at $6K in Q4 2021. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

  • Surevest held 206 shares of Myriad Genetics worth $4K as of Q3 2022.
  • Surevest left its Myriad Genetics share count unchanged in Q3 2022.
  • Myriad Genetics made up ﹤0.01% of Surevest's portfolio in Q3 2022, its #340 holding.
  • Surevest first reported a position in Myriad Genetics in Q4 2021 and has held it in 4 quarters since.
  • Surevest's Myriad Genetics position peaked at $6K in Q4 2021.
  • 191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Surevest's 13F filing for Q3 2022, filed 14 Nov 2022.